NBQX

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione) is a potent antagonist for AMPA receptors and (to a lesser extent) kainate receptors, both of which are types of ionotropic glutamate receptor. It is used in scientific research and has no role in medicine, as it is a toxic compound with a number of potential side effects.

Mechanism of action

NBQX acts by blocking the action of glutamate, the main excitatory neurotransmitter in the brain. It does this by binding to the AMPA and kainate types of glutamate receptor, which prevents the activation of these receptors by glutamate. This reduces the flow of ions into the neuron, which inhibits the neuron's ability to generate an action potential.

Uses in research

NBQX is used in research to study the role of AMPA and kainate receptors in various neurological and psychiatric disorders. It is also used to investigate the mechanisms of excitotoxicity, a process in which excessive activation of glutamate receptors leads to neuronal damage or death.

Side effects

As a potent antagonist of glutamate receptors, NBQX has a number of potential side effects. These include neurotoxicity, seizures, and psychosis. However, these side effects are generally only seen at high doses.

See also

• Glutamate receptor
• AMPA receptor
• Kainate receptor
• Excitotoxicity

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  NBQX molecule spacefill